ETF Holdings Breakdown of PRME

PRME institutional holdings

The adjusted close for PRME on 2025-11-11 was 3.92

The following institutional investment holdings of PRME have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	112,274	USD 440,114	3.92
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	112,274	USD 440,114 10.1%	3.92
Total =		224,548	USD 880,228

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with PRME

Prime Medicine, Inc. (NYSE:PRME) Receives $8.92 Consensus Target Price from Analysts

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong […] - 2025-09-15 02:30:21

Prime Medicine (NASDAQ:PRME) Stock Price Down 3.7% on Analyst Downgrade

Prime Medicine, Inc. (NASDAQ:PRME – Get Free Report)’s share price was down 3.7% on Tuesday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The stock traded as low as $3.09 and last traded at $3.12. Approximately 3,103,838 shares traded hands during mid-day trading, a decline of 4% from […] - 2025-09-04 02:20:47

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

Prime Medicine, Inc. (NYSE:PRME – Get Free Report)’s share price gapped up prior to trading on Monday after an insider bought additional shares in the company. The stock had previously closed at $4.04, but opened at $4.35. Prime Medicine shares last traded at $4.56, with a volume of 960,713 shares changing hands. Specifically, major shareholder […] - 2025-08-05 02:22:50

Prime Medicine, Inc. (NYSE:PRME) Given Average Recommendation of “Moderate Buy” by Brokerages

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has received an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the […] - 2025-07-24 05:11:01

Investors Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock traders purchased 3,683 call options on the stock. This is an increase of approximately 361% compared to the average volume of 799 call options. Insider Transactions at Prime Medicine In other news, major shareholder David […] - 2025-07-08 02:19:51

Bank of America Corp DE Cuts Stock Holdings in Prime Medicine, Inc. (NYSE:PRME)

Bank of America Corp DE trimmed its holdings in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 11.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 430,613 shares of the company’s stock after selling 54,512 shares during the period. […] - 2025-06-06 04:37:00

BNP Paribas Financial Markets Takes Position in Prime Medicine, Inc. (NYSE:PRME)

BNP Paribas Financial Markets bought a new stake in Prime Medicine, Inc. (NYSE:PRME – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 20,096 shares of the company’s stock, valued at approximately $59,000. Other institutional investors and hedge […] - 2025-06-03 04:58:53

Prime Medicine (NYSE:PRME) Receives “Neutral” Rating from Citigroup

Prime Medicine (NYSE:PRME – Get Free Report)‘s stock had its “neutral” rating restated by equities researchers at Citigroup in a research note issued to investors on Tuesday, Marketbeat.com reports. They presently have a $1.50 price objective on the stock, down from their prior price objective of $10.00. Citigroup’s price target would indicate a potential upside […] - 2025-05-29 02:15:12

JMP Securities Cuts Prime Medicine (NYSE:PRME) Price Target to $6.00

Prime Medicine (NYSE:PRME – Free Report) had its price target trimmed by JMP Securities from $10.00 to $6.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a market outperform rating on the stock. PRME has been the topic of a number of other reports. Wall Street Zen raised Prime Medicine […] - 2025-05-23 05:09:02

Chardan Capital Has Lowered Expectations for Prime Medicine (NYSE:PRME) Stock Price

Prime Medicine (NYSE:PRME – Get Free Report) had its price target decreased by stock analysts at Chardan Capital from $16.00 to $12.00 in a report released on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. A number of other research analysts have also recently commented on PRME. StockNews.com raised shares of […] - 2025-05-21 05:14:50

Balyasny Asset Management L.P. Purchases New Holdings in Prime Medicine, Inc. (NYSE:PRME)

Balyasny Asset Management L.P. purchased a new stake in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 16,342 shares of the company’s stock, valued at approximately $48,000. A number of other hedge funds […] - 2025-05-20 04:42:56

Head to Head Review: Prime Medicine (NYSE:PRME) and BioCryst Pharmaceuticals (NASDAQ:BCRX)

Prime Medicine (NYSE:PRME – Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Valuation and Earnings This table compares Prime Medicine […] - 2025-05-20 02:46:51

Wells Fargo & Company MN Lowers Holdings in Prime Medicine, Inc. (NYSE:PRME)

Wells Fargo & Company MN trimmed its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 43.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 96,181 shares of the company’s stock after selling 75,287 shares during the period. Wells Fargo & Company MN’s holdings in Prime Medicine were worth $281,000 as […] - 2025-05-07 04:24:56

XTX Topco Ltd Makes New Investment in Prime Medicine, Inc. (NYSE:PRME)

XTX Topco Ltd purchased a new position in Prime Medicine, Inc. (NYSE:PRME – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 14,466 shares of the company’s stock, valued at approximately $42,000. Other hedge funds have also bought and sold shares of the […] - 2025-05-02 05:10:54

Prime Medicine, Inc. (NYSE:PRME) Shares Acquired by Walleye Capital LLC

Walleye Capital LLC increased its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 272.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 403,739 shares of the company’s stock after purchasing an additional 295,365 shares […] - 2025-04-21 05:16:56

Prime Medicine, Inc. (NYSE:PRME) Receives $13.38 Consensus Price Target from Analysts

Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been given a consensus recommendation of “Buy” by the nine analysts that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year […] - 2025-04-18 02:28:53

Critical Review: Prime Medicine (NYSE:PRME) and Pluri (NASDAQ:PLUR)

Pluri (NASDAQ:PLUR – Get Free Report) and Prime Medicine (NYSE:PRME – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Risk & Volatility Pluri has a beta of […] - 2025-04-15 02:44:49

Prime Medicine (NYSE:PRME) Receives “Outperform” Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note published on Tuesday,RTT News reports. The firm currently has a $13.00 price target on the stock, up from their prior price target of $12.00. A number of other research firms have also recently commented on PRME. StockNews.com […] - 2025-03-19 04:40:51

Reviewing Prime Medicine (NYSE:PRME) & Bio-Techne (NASDAQ:TECH)

Prime Medicine (NYSE:PRME – Get Free Report) and Bio-Techne (NASDAQ:TECH – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk. Risk & Volatility Prime Medicine has a beta of […] - 2025-02-28 05:00:48

Prime Medicine, Inc. (NYSE:PRME) Receives $13.13 Average Target Price from Brokerages

Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has been assigned an average rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target […] - 2025-02-27 04:09:13

Prime Medicine (NYSE:PRME) versus Qiagen (NYSE:QGEN) Financial Review

Prime Medicine (NYSE:PRME – Get Free Report) and Qiagen (NYSE:QGEN – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings. Insider & Institutional Ownership 70.4% of Prime Medicine shares […] - 2025-02-19 04:12:57

Prime Medicine (NYSE:PRME) Upgraded at StockNews.com

StockNews.com upgraded shares of Prime Medicine (NYSE:PRME – Free Report) to a sell rating in a report released on Tuesday. A number of other equities research analysts have also recently issued reports on PRME. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Prime Medicine in a research note […] - 2025-02-14 06:32:51

Sumitomo Mitsui Trust Group Inc. Sells 100,275 Shares of Prime Medicine, Inc. (NYSE:PRME)

Sumitomo Mitsui Trust Group Inc. lessened its position in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,090,180 shares of the company’s stock after selling 100,275 shares during the […] - 2025-02-13 08:16:49

China Universal Asset Management Co. Ltd. Buys 4,725 Shares of Prime Medicine, Inc. (NYSE:PRME)

China Universal Asset Management Co. Ltd. grew its stake in shares of Prime Medicine, Inc. (NYSE:PRME – Free Report) by 20.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 27,811 shares of the company’s stock after acquiring an additional 4,725 shares during the quarter. […] - 2025-02-04 07:14:55

Brokerages Set Prime Medicine, Inc. (NYSE:PRME) PT at $13.13

Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have received a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month […] - 2025-02-04 06:36:56

Prime Medicine (NYSE:PRME) and Windtree Therapeutics (NASDAQ:WINT) Critical Survey

Prime Medicine (NYSE:PRME – Get Free Report) and Windtree Therapeutics (NASDAQ:WINT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations. Insider & Institutional Ownership 70.4% of Prime […] - 2025-02-04 04:46:59

Back to Listing

Disclaimer